Novartis May Turn Sandoz into Separate Entity Amidst Restructuring
Rather than selling, Novartis could spin Sandoz off into its own separate entity with its own listing on a stock exchange.
The Home of the Life Sciences Industry
Hyloris' Post-Op Pain Treatment Stalled by CRL from FDA
Hyloris did not provide details on the FDA's concern but said it will fully comply with whatever is necessary to move the product forward.
More Top Stories
- Continuing Transformation, Bayer Opens Genetown Research and Innova...
- After Layoffs, Big Companies Advance and Small Firms Retrench
- FDA Reportedly OK's Future Trial For Pig-to-Human Organ Transplanta...
- NYU Researchers Create Synthetic Versions of Hox Genes
- FDA Declines EAU, SCOTUS' Thomas Weighs in on Vaccine & More COVID-...
